Smart therapeutic strategies in immuno-oncology
Authors:
- 4 March 2014
- journal article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 11 (4) , 181-182
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- MC13-0045 Genes from the TP53 network and their role in ovarian cancer prognosis and response to chemotherapyEuropean Journal of Cancer, 2013
- Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodiesEuropean Journal of Cancer, 2013
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaNew England Journal of Medicine, 2013
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Hepatotoxicity with Combination of Vemurafenib and IpilimumabNew England Journal of Medicine, 2013
- Immunogenic Cell Death in Cancer TherapyAnnual Review of Immunology, 2013
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaNew England Journal of Medicine, 2012